Tag Archives: CDC

World TB Day

PrintToday is World TB Day.

It is a day that gives us each the space to better understand the magnitude of the TB threat, mourn the loss of the more than 1 million people worldwide who die of TB each year, recognize the tragic consequences for their loved ones and for economic stability in impoverished nations, and express gratitude for those who conduct TB research, finance and deploy on-the-ground interventions, and advocate for the resources needed to conquer this vicious killer.

TB is the second most common cause of death from infectious disease, after HIV/AIDS. In 2012, approximately 8.6 million developed TB and 1.3 million died from the disease, with the death rate particularly high among HIV-positive patients.

There is good news on the TB front: infection rates have been falling for a decade and the mortality rate has dropped 45% since 1990. These results are in line with the millennial development goals, which set TB control metrics for 2015. Unfortunately, progress against other targets is lagging, including a slower than hoped for reduction in the prevalence of active TB and highly disappointing results in the diagnosis and treatment of multi-drug resistant TB (MDR-TB).

In the US, it’s far too easy — and a dangerous mistake — to dismiss the significance of tuberculosis. It is true that gone are the days when TB was prevalent in the US, the days when Americans were quarantined to reduce the infection rate and sent to sanitariums for treatment that sometimes worked…and too often didn’t. But with global travel, TB is entering our country, and with drug-resistant forms of the infection spreading, American lives are at risk. There have even been cases reported of totally-drug resistant TB, which means that resistance has been detected in every known treatment. The implications of an outbreak of totally drug resistant TB in the US are as ominous as they are in developing countries, particularly for those with compromised immune systems.

So what’s next? Our role as a global leader and our identity as a compassionate people underscore the importance of robust American support for the Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as robust appropriations for USAID and other on-the-ground efforts to combat TB. For sake of Americans and the global community, the National Institutes of Health and the Centers of Disease Control and Prevention must be resourced sufficiently to develop new TB treatments, identify new prevention strategies, and assist in global TB control.

And it is important to acknowledge philanthropic and private sector efforts to combat TB, including the work of RESULTS, the Gates Foundation, and companies such as Johnson and Johnson.

When 1.3 million people die each year from an infectious disease that poses a renewed threat to the United States, waging war against that disease is not an option, it is an imperative.

Tell Congress to Make Medical Progress a High Priority in the 2015 Appropriations Process

The House and the Senate have begun deliberations on funding levels for NIH, CDC, AHRQ, NSF and FDA for FY15. Pressure to cut federal spending this midterm election year is enormous, and we need advocates to reach out to their representatives. Members in both houses of Congress are accepting input from constituents on which priorities they should fight for. Let your representatives know that combating disabling and deadly diseases is a national imperative, and funding for the agencies committed to this fight should be included on their list of appropriations priorities. Contact them TODAY and share this alert on Facebook, Twitter and with your networks.

Take action!

A Weekly Advocacy Message from Mary Woolley: Dead on Arrival

Dear Research Advocate:

The president’s budget for FY15 was released Tuesday. While mostly symbolic, the president’s funding recommendations often serve as the “first bid” in the negotiations that result in agency funding levels. That is why the president’s proposals for the agencies that collectively drive medical progress and play such a pivotal role in the health and safety of Americans are of such concern.

The president’s budget proposes only slight increases for NIH, FDA and NSF in FY15, and significant cuts for CDC and AHRQ. As I said in The Huffington Post and in other media, President Obama’s budget does not reflect the potential the U.S. has to advance scientific discovery or medical progress; he sets the bar — and the nation’s sights — much too low! At a time when our global leadership is on thin ice, America needs a bold plan to advance research and innovation. See Research!America’s statement on the president’s budget here. Continue reading →

Statement by Research!America President and CEO Mary Woolley on President Obama’s FY15 Budget

The president’s budget does not reflect the potential the U.S. has to advance scientific discovery. While welcome, the minor increases for the National Institutes of Health, the National Science Foundation, and the Food and Drug Administration diminish our ability to accelerate the pace of medical innovation, which saves countless lives, helps our nation meet its solemn commitment to wounded warriors, and is a major driver of new businesses and jobs. We’re also disappointed with reduced funding for the Agency for Healthcare Research and Quality and the Centers for Disease Control and Prevention. AHRQ and CDC cannot be neglected in the name of deficit reduction, and it is truly disturbing that the president’s budget treats those crucial agencies in that manner. The capacity to improve health outcomes and health care efficiency, stem the explosion in chronic diseases, and protect the security of our nation in the face of lethal, drug-resistant infections and international pandemics all hinge on the expertise and resources available to these agencies. We must expand investigations into cancer clusters, deadly meningitis outbreaks and research crucial to bioterrorism preparedness, not reverse course. These funding levels also jeopardize our global leadership in science — in effect ceding leadership to other nations as they continue to invest in strong R&D infrastructures that have already begun to attract our best and brightest innovators. We simply cannot sustain our nation’s research ecosystem, combat costly and deadly diseases like Alzheimer’s and cancer, and create quality jobs with anemic funding levels that threaten the health and prosperity of Americans. The administration and Congress must work together to boost funding for federal research and health agencies in FY15 and end the sequester in order to truly meet the level of scientific opportunity.

A Weekly Advocacy Message from Mary Woolley: Promising process; disappointing progress

Dear Research Advocate:

The omnibus appropriations bill about to become law demonstrates that bipartisanship and pseudo-regular order is achievable. We won’t know for sure if we have true “regular order” until Congress proceeds through the FY15 appropriations process in a timely manner — something that hasn’t happened for many years. The importance of regular order is that the public’s interests are heard from in hearings, and every Member of Congress participates in priority-setting instead of only having the opportunity to cast a single up-or-down vote. Regular order is worth working toward, since at least one priority we all care about did not fare well in the omnibus.

The omnibus has failed to fund NIH at a level that fully reverses the impact of sequestration on the agency’s baseline funding level, much less establishes a growth trend that can fully unleash the potential inherent in the sequencing of the human genome and other research breakthroughs. As Drs. Paul Stoffels and Alan Leshner make crystal clear in an op-ed in Politico Magazine, we can’t settle for “better than sequestration.” If our nation wants to thrive, we need to grow our investment in science. Between 2010 and 2013, U.S. federal investments in science fell to less than 1% (.82%) of the economy. That’s the lowest it’s been in 50 years! As you know, this comes at a time when foreign nations are rapidly ramping up their R&D programs and taking a page from our playbook. Remember that global competitiveness in medical research is a pivotal determinant of our global economic competitiveness overall. We aren’t just talking about the future of our scientific enterprise, we are talking about the future of our economy. Are we truly willing to cede leadership in global R&D? (See also our statement cited in The Hill and other media outlets, as well as my interview today with UDC.) Continue reading →

Statement by Research!America president and CEO Mary Woolley on Omnibus Bill

We applaud portions of the omnibus bill that support the nation’s research, innovation and public health ecosystem, which works to assure our future health and economic well-being. The growth in funding for the Food and Drug Administration, fueled in part by the common-sense return of the 2013 user fees, as well as the increases for the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality and the National Science Foundation are welcome news.

But funding for the National Institutes of Health has been kept well below the level of scientific opportunity. We must eliminate sequestration once and for all, and grow our investment in NIH in order to slow and halt the progression of diseases and disabilities ranging from Alzheimer’s to diabetes to traumatic brain injury. The appropriators have worked in good faith to move the nation forward.  But as long as Congress avoids the primary issues fueling our national debt – tax and entitlement reform – it will be difficult to invest robustly in solutions to our problems.

 ###

A Weekly Advocacy Message from Mary Woolley: Pope Francis is the Man of the Year; do you know what the Word of the Year is?

Dear Research Advocate:

Here’s a holiday surprise! I am not referring to the budget deal, but to the fact that Merriam-Webster’s 2013 word of the year — determined via the greatest increase in online searches — is “science.” I find this to be refreshing news, providing evidence that interest in science is growing, which in turn is an indication of substantial room for researchers and research advocates to contribute to public understanding and support of science. We appear to have an opportunity ready for the taking to overcome the “invisibility” problem that contributes to holding decision makers back from assigning a higher priority to science.

And speaking of those decision makers, we have a budget deal! While modest at best, it is a starting point for bipartisanship in serving the public’s interest. We can build on this foundation. Please add your voice, as funding is being determined by appropriators. Click here to urge your Members of Congress to support robust funding for NIH, NSF, FDA, CDC and AHRQ. This week, we’ve released our annual Health R&D Investment report, which could provide new context for your messages. The report shows some gains in philanthropy, industry, and voluntary health association support for research but notes woefully inadequate federal funding, especially given what’s at stake for our health and our economy. Continue reading →

A Weekly Advocacy Message from Mary Woolley: “It always seems impossible until it’s done”– Nelson Mandela

Dear Research Advocate:

As I’m sure you’ve heard, the Joint Budget Committee released a two-year budget agreement Tuesday night. The package involves $63 billion in partial sequestration relief over two years, offset by fees (not taxes!) and a wide variety of cost-sharing arrangements, AKA “pay fors.” While it remains unclear whether user fees will be subjected to any sequester in 2014 and 2015, the already-sequestered FDA user fees are locked up and cannot be used to accelerate medical advances. This is a missed opportunity that patients can’t afford. While not a perfect deal in many respects, the House is expected to approve the Murray-Ryan budget deal within moments, and the Senate is expected to pass it next week.

For the advocacy community, the overall budget number is important, but the appropriations process that follows is crucial. The funding levels for NIH, CDC and AHRQ depend on the funding allocated to the Labor-H subcommittee and the FDA on the Agricultural subcommittee. Since dealmakers have not dealt with tax or entitlement reform, this will involve robbing Peter to pay Paul, and it won’t be pretty. Decisions will be made soon, as Congress is working against a January 15 deadline. Please consider contacting your Members of Congress to urge them to weigh in on how funding is allocated to appropriators and, in short order, allocated by appropriators — ask them to maximize funding for NIH, CDC, AHRQ, FDA and NSF. A report released this week by United for Medical Research, featuring a collection of stories about the negative impact that sequestration has had on NIH as well as the impact on individual research laboratories, can help you make the case. Continue reading →

Tell Congress to Protect Medical and Health Research

To protect medical and health research, policy makers must eliminate sequestration. This remains Research!America’s top-line message, because it is sequestration that poses the greatest threat to all discretionary funding, including medical and health research conducted by NIH, CDC, FDA, NSF, AHRQ, DOD … and the list goes on. Advocates for medical and health research have made a huge impact over the years on funding and policies supportive of medical and health research, including playing a key role in reducing sequestration in 2013. We are asking you to weigh in again to help address sequestration in FY14 and FY15.

On Wednesday, the co-chairs of the committee charged with establishing an overall budget number for FY14 struck a deal that would establish this top-line number for both FY14 and FY15. Under this agreement, the sequestration cuts would be reduced by $50-$60 billion over the two-year period (a reduction of approximately 30% each year). While this modest reduction is less than hoped for, it does signal progress in the fight against sequestration. The task now is to assure this or a better deal passes both the House and Senate by December 13.

Please contact your representatives in Congress and urge them to vote in favor of a significant reduction in sequestration for FY14 and FY15 as a down payment on eliminating sequestration.

Take action now.

Public Health Thank You Day: Recognizing All Levels of Public Health Work

To address the recent meningitis outbreak at Princeton, public health programs from all levels got involved. Students sought medical attention at the university’s health center and their hometown local hospitals; the New Jersey Department of Health (NJDOH) investigated the outbreak and requested CDC involvement; the FDA examined the case and allowed a new vaccine, unlicensed in the US but approved in Europe and Australia. With final CDC approval, the university will offer the vaccine on campus and cover the cost for all students.

580491_520295697990810_1202890633_nDiverse institutions within our public health infrastructure came together to address the outbreak, and the public health professionals within them did what was needed—as they do in communities across the country. On November 25th, Research!America and other leading health organizations will come together to thank them and all other public health heroes like them. Join us! Connect with us on Facebook (and use #PHTD on Twitter), write to your policymakers, submit a letter to the editor to your local paper (see York Daily Record  and Beaufort County Now examples), and more.

 

Research!America and Partners Applaud Public Health Heroes for Keeping Us Safe 24/7

Public Health Thank You Day — November 25, 2013

ALEXANDRIA, Va.—November 21, 2013—On the Monday before Thanksgiving, Research!America and partners urge Americans to pay tribute to public health professionals who work around the clock to protect our health. Public Health Thank You Day honors unsung heroes who keep our drinking water safe and air clean, develop vaccines, track and investigate infections, and protect us from natural and man-made threats. These everyday heroes include our health inspectors, environmental health scientists, public health researchers, sanitation workers and many other dedicated workers.

“Professionals throughout the public health system work 24/7 to protect Americans from health threats,” said Centers for Disease Control and Prevention (CDC) Director Thomas R. Frieden, MD, MPH. “The recent federal shutdown was a stark reminder of how much we rely on these professionals day in and day out to detect outbreaks, respond to health emergencies and promote health every day. Their dedication reflects their scientific ethic as well as their continuing commitment to serving the public.” Continue reading →

A Weekly Advocacy Message from Mary Woolley: Moving from the Envy of the World to the Puzzle of the World

Dear Research Advocate:

NIH Director Francis Collins was recently interviewed for a Wall Street Journal article that would reinvigorate even the weariest research advocate. Dr. Collins captured the legacy and unprecedented potential of research for health, as well as the counterintuitive neglect of it, in a truly compelling manner. Dr. Collins made similarly captivating comments yesterday at the Washington Ideas Forum: “We’re going from the envy of the world,” he said, “to the puzzle of the world. Other nations are mystified that we have stopped following our own playbook — the one they are using now to drive their economy and improve health and quality of life for their own populations.”

Of course they’re mystified. Policy makers are setting Americans up for needless suffering and America up for decline. It’s past time to follow the lead of, for example, the Australian government; despite battling austerity, it has announced an increase in funding for the Australian Research Council’s research grants. And Australia is not alone — China is now on track to overtake U.S. spending (actual spending and as a percentage of GDP) within five years. Continue reading →

Public Health Thank You Day, November 25

580491_520295697990810_1202890633_nAs recent disease outbreaks have demonstrated, the need for public health is around the clock. But sequestration, across-the-board spending cuts, presents major challenges for the Centers for Disease Control and Prevention (CDC) and other federal health agencies.  Among them: depleted resources for immunizations, reduced support to state and local health departments, and deep cuts to programs to prevent cancer, heart attacks, strokes, and diabetes. In spite of the challenges, public health professionals continue to dedicate their time and energy to addressing major health threats.

CDC employees are among the many public health professionals who show tireless commitment to preventing disease and promoting good health. Health educators instruct children on the long-term effects of lifestyle choices; researchers pursue new treatments for evolving illnesses; regulators ensure prescription drug safety and effectiveness; physicians implement vaccination programs. They are public health heroes, working every day to improve others’ quality of life. Continue reading →

2013 Canada Gairdner Awards

Since 1959, the Canada Gairdner Awards recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life. Among the world’s most esteemed medical research prizes, the awards distinguish Canada as a leader in science and provide a $100,000 prize to each scientist for their work.

Four U.S. scientists are among this year’s winners:

  • Canada awardHarvey J. Alter, MD and Daniel W. Bradley, PhD received the Canada Gairdner International Award for their contributions to the discovery and isolation of the hepatitis C virus. Dr. Alter is a senior investigator and Chief Infectious Diseases Section and associate director for research, Department of Transfusion Medicine at the National Institutes of Health. Dr. Bradley is a consultant for infectious diseases viral hepatitis at the Centers for Disease Control and Prevention.
  • Stephen Joseph Elledge, PhD, received the Canada Gairdner International Award for his work in DNA repair. Dr. Elledge is a Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School. Continue reading →

It’s Time to Kick Sequestration to the Curb, Not Down the Road!

Urge your Members to protect medical research in upcoming Budget Conference Committee discussions

Sequestration’s arbitrary, across-the-board budget cuts to defense and non-defense spending have ravaged (and will continue to ravage) our research enterprise. The Budget Conference Committee, which was negotiated as part of reopening the government and preventing the U.S. from defaulting on debts, has an opportunity to replace sequestration as they develop their “long-term budget solution” by December 13. Sequestration is rendering it virtually impossible to maintain, much less increase the budgets of NIH, NSF, FDA, and CDC; if it is not stopped, their budgets will almost certainly decline for the next nine years, regardless of scientific opportunity, public health needs, or the preferences of Americans.  Funding cuts are stopping highly promising research in its tracks, squandering exciting new potential for treatments and cures for millions of Americans who are waiting for them.

Deficit reduction is important, but there are ways to achieve it that do not compromise American lives and American competitiveness. Arbitrary budget cuts that abandon medical research are wrong, and it’s time we kicked them to the curb and not down the road!

Take action now.